Semaglutide Dosage Guide: Titration, Maintenance & Adjustments
Complete semaglutide dosage guide covering titration schedules for Wegovy, Ozempic, and Rybelsus — with clinical evidence, dose adjustment tips, and missed dose protocols.
Medically Reviewed
Reviewed by Dr. James Chen, MD, PhD, FACE on March 7, 2026
Our medical review process ensures clinical accuracy and patient safety.
Introduction
Semaglutide has transformed the treatment landscape for obesity and type 2 diabetes. Available as once-weekly subcutaneous injections (Ozempic, Wegovy) and a daily oral tablet (Rybelsus), it is one of the most extensively studied GLP-1 receptor agonists in history. Yet getting the dosage right — and knowing when and how to adjust it — makes a significant difference in both efficacy and tolerability.
The landmark STEP 1 trial established that semaglutide 2.4 mg once weekly, combined with lifestyle intervention, produced a mean body weight reduction of 14.9% over 68 weeks — with 86% of participants losing at least 5% of their baseline weight.
Evidence: "Participants who received semaglutide had a mean change in body weight of −14.9%, as compared with −2.4% for placebo." — Wilding JPH, et al. N Engl J Med. 2021. DOI: 10.1056/NEJMoa2032183
This guide consolidates the current clinical evidence on semaglutide dosing across all approved formulations — from the initial injection to maintenance dosing, managing side effects, and navigating missed doses.
Semaglutide Formulations: Which Dose Applies to You?
Before reviewing specific titration schedules, it is essential to understand that semaglutide comes in three distinct products with different approved dosing ranges:
| Brand | Route | Indication | Dose Range |
|---|---|---|---|
| Wegovy | Subcutaneous injection (weekly) | Chronic weight management | 0.25 mg → 2.4 mg |
| Ozempic | Subcutaneous injection (weekly) | Type 2 diabetes | 0.25 mg → 2.0 mg |
| Rybelsus | Oral tablet (daily) | Type 2 diabetes | 3 mg → 14 mg |
These are not interchangeable. Wegovy pens contain different concentrations than Ozempic pens, and Rybelsus absorption follows completely different pharmacokinetics.
Wegovy Dosage Schedule (Weight Management)
The FDA-approved semaglutide 2.4 mg titration for chronic weight management follows a structured 16-week ramp-up designed to minimize gastrointestinal side effects while allowing the body to adapt.
Standard Titration Protocol
| Period | Dose | Duration |
|---|---|---|
| Weeks 1–4 | 0.25 mg once weekly | 4 weeks |
| Weeks 5–8 | 0.5 mg once weekly | 4 weeks |
| Weeks 9–12 | 1.0 mg once weekly | 4 weeks |
| Weeks 13–16 | 1.7 mg once weekly | 4 weeks |
| Week 17 onward | 2.4 mg once weekly | Maintenance |
The 0.25 mg starting dose is not a therapeutic dose — it exists solely to establish tolerability. Meaningful appetite suppression and weight loss effects typically become noticeable from 0.5 mg onward.
When Weight Loss Is Insufficient
Clinical guidelines support staying at a lower dose if the patient is losing weight meaningfully and tolerating the medication well. However, if weight loss plateaus and the patient is tolerating the current dose, the target is 2.4 mg weekly.
The STEP 4 trial demonstrated that patients who discontinued semaglutide after 20 weeks — having achieved substantial weight loss — regained most of the lost weight within one year, underscoring the importance of maintaining effective dosing long-term.
Evidence: "By week 68, participants continuing semaglutide had lost a further 7.9% of body weight from randomization, versus a gain of 6.9% in the placebo-switched group." — Wadden TA, et al. JAMA. 2021. DOI: 10.1001/jama.2021.3224
Ozempic Dosage Schedule (Type 2 Diabetes)
Ozempic follows a simpler titration compared to Wegovy, with a lower maintenance ceiling for its primary diabetes indication.
Standard Titration Protocol
| Period | Dose | Duration |
|---|---|---|
| Weeks 1–4 | 0.25 mg once weekly | 4 weeks (initiation only) |
| Week 5 onward | 0.5 mg once weekly | Minimum maintenance |
| After ≥4 weeks at 0.5 mg | 1.0 mg once weekly | If additional glycemic control needed |
| After ≥4 weeks at 1.0 mg | 2.0 mg once weekly | Maximum approved dose |
Ozempic 2.0 mg was approved by the FDA in 2022, supported by evidence from the SUSTAIN FORTE trial demonstrating superior HbA1c reduction compared to 1.0 mg. Many clinicians note meaningful weight loss benefits at all dose levels, though the 1.0–2.0 mg range produces the most robust effects.
Rybelsus Dosage Schedule (Oral, Type 2 Diabetes)
Oral semaglutide requires a unique titration because bioavailability is highly sensitive to food, water volume, and timing.
Titration Protocol
| Period | Dose | Duration |
|---|---|---|
| Weeks 1–4 (Month 1) | 3 mg once daily | 4 weeks (tolerability only) |
| Weeks 5–8 (Month 2) | 7 mg once daily | Maintenance or stepping stone |
| After ≥4 weeks at 7 mg | 14 mg once daily | Maximum dose if needed |
Critical Administration Rules for Rybelsus
- Take on an empty stomach upon waking
- Swallow with no more than 4 oz (120 mL) of plain water
- Wait at least 30 minutes before eating, drinking anything else, or taking other medications
- Do not crush or chew the tablet
These rules exist because Rybelsus contains an absorption enhancer (SNAC) that facilitates gastric uptake — any disruption can reduce bioavailability by up to 50%.
Managing Side Effects and Dose Adjustments
Gastrointestinal adverse events — primarily nausea, vomiting, diarrhea, and constipation — are the most common reason patients discontinue semaglutide, and nearly all occur during the dose-escalation phase.
Evidence: "Nausea occurred in 43.9% of patients on semaglutide 2.4 mg vs 16.1% on placebo, with a median duration of 8 days; most events were mild-to-moderate in severity." — Davies M, et al. Obesity. 2022. DOI: 10.1002/oby.23232
Dose Adjustment Protocol for Tolerability
If a patient cannot tolerate a scheduled dose increase:
- Delay escalation — Hold the current dose for an additional 4 weeks before attempting the next increase
- Step down temporarily — If the 2.4 mg maintenance dose is not tolerated, reduce to 1.7 mg for up to 4 weeks, then re-escalate
- If intolerance persists at any dose level, discuss discontinuation and alternatives with the prescribing provider
Practical Tips to Reduce GI Side Effects
- Eat smaller, more frequent meals
- Avoid high-fat, high-sugar, or fried foods — these slow gastric emptying further
- Stop eating as soon as you feel full (semaglutide amplifies satiety signals)
- Avoid eating within 2–3 hours of bedtime
- Stay well hydrated throughout the day
- Short-term use of antiemetics (e.g., ondansetron) may be appropriate in consultation with a provider
Missed Dose Protocol
The once-weekly schedule means missing a dose occasionally is common. The protocol depends on how much time has elapsed:
| Time Since Missed Dose | Action |
|---|---|
| ≤ 5 days since missed dose | Administer the missed dose as soon as remembered |
| > 5 days since missed dose | Skip the missed dose; resume next scheduled weekly dose |
Never administer two doses within the same week to "catch up." Resume the regular weekly dosing day after skipping.
For Rybelsus, if a daily dose is missed, skip it entirely for that day — do not double up the following morning.
Cardiovascular Benefit: Why Dosing Matters Long-Term
One of the most compelling reasons to reach and maintain the full 2.4 mg maintenance dose is the cardiovascular benefit documented in the SELECT trial — the largest cardiovascular outcomes trial in obesity to date (17,604 participants with pre-existing cardiovascular disease but without diabetes).
Evidence: "Semaglutide 2.4 mg weekly reduced the incidence of major adverse cardiovascular events by 20% vs placebo (HR 0.80; 95% CI 0.72–0.90; P<0.001) over a mean follow-up of 39.8 months." — Lincoff AM, et al. N Engl J Med. 2023. DOI: 10.1056/NEJMoa2307563
This cardiovascular benefit — independent of diabetes status — reinforces that semaglutide is not simply a weight-loss drug. The dose matters: the SELECT trial used 2.4 mg, and it is unclear whether lower doses confer the same degree of cardiovascular protection.
Special Populations and Dose Considerations
Adolescents (12–17 years)
The FDA approved Wegovy for adolescents with obesity in 2022. The titration schedule mirrors the adult protocol (0.25 mg → 2.4 mg over 16 weeks). The STEP TEENS trial demonstrated a 16.1% mean reduction in BMI at 68 weeks versus 0.6% with placebo.
Renal Impairment
No dose adjustment is required for patients with chronic kidney disease, including those on dialysis, based on pharmacokinetic data. Semaglutide is not renally cleared.
Hepatic Impairment
No dose adjustment is required. However, the oral formulation (Rybelsus) has limited data in severe hepatic impairment and should be used cautiously in this population.
Pregnancy and Breastfeeding
Semaglutide is contraindicated during pregnancy. Discontinue at least 2 months before a planned pregnancy given the drug's long half-life (~1 week). Use effective contraception throughout treatment.
Conclusion: Key Takeaways
The semaglutide dosage schedule is not arbitrary — the 16-week titration is specifically engineered to reduce gastrointestinal side effects while the body adapts to slowed gastric emptying. Key principles:
- Start low, go slow: Never skip the titration phase
- The goal is the maintenance dose: 2.4 mg (Wegovy) or 2.0 mg (Ozempic) deliver the most robust clinical outcomes
- Tolerability issues are manageable: Delay, step down, adjust diet — rarely is discontinuation the first resort
- Missing one dose is fine: Follow the 5-day rule; never double-dose
- Long-term use is evidence-based: The SELECT trial establishes cardiovascular benefit; STEP 4 confirms weight regain upon discontinuation
For more on what to expect during the first weeks, see Starting GLP-1: What to Expect. For a head-to-head comparison with tirzepatide, see Mounjaro vs Ozempic.
References
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002. DOI: 10.1056/NEJMoa2032183
Davies M, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971–984. DOI: 10.1016/S0140-6736(21)00213-0
Wadden TA, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1403–1413. DOI: 10.1001/jama.2021.3224
Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221–2232. DOI: 10.1056/NEJMoa2307563
Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity. Obesity. 2022;30(3):631–641. DOI: 10.1002/oby.23232
Aroda VR, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide: Insights from the SUSTAIN 1–7 trials. Diabetes Metab. 2019;45(5):409–418. PubMed
Last updated: 2026-03-07 Medical review: Dr. James Chen, MD, PhD, FACE
Tags
Written By
Dr. Sarah Mitchell
Medical Director, MD, FACP
Dr. Sarah Mitchell is a board-certified internist specializing in metabolic medicine and weight management. With over 15 years of clinical experience, she has helped thousands of patients achieve sustainable weight loss through evidence-based approaches.
Medical Reviewer
Dr. James Chen
Endocrinologist, MD, PhD, FACE
Dr. James Chen is a fellowship-trained endocrinologist with expertise in diabetes, metabolism, and hormone-related weight disorders. His research on GLP-1 receptor agonists has been published in leading medical journals.
Editorial Standards
This article follows our strict editorial guidelines. All content is based on peer-reviewed research and reviewed by medical professionals. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.